Research Article
BibTex RIS Cite

In-vivo examination of nasal-to-brain administration for delivering rhodamine B nanospanlastic for fluorescent vesicle imaging

Year 2026, Volume: 30 Issue: 2, 569 - 575, 15.03.2026
https://doi.org/10.12991/jrespharm.1909321
https://izlik.org/JA79AE45SE

Abstract

This study investigated the efficacy of nasal injection of rhodamine B nanospanlastic (RBN) for magnetic vesicle imaging of specific brain locations. Effective delivery of RBN, which functions as fluorescence agents, to specific brain regions is necessary to achieve fluorescence particle imaging (FPI). There has been interest in nasal administration as a means of administering drugs directly to the brain, thereby circumventing the blood-brain barrier. We offered experimental nasal fluorescence agent administration by in vivo research. Fluorescent tests confirmed that, upon nasal delivery, the intended nanospanlastic migrated into the brain. Furthermore, using fluorescent microscopy, we demonstrated how these nanospanlastics accumulate in specific target regions. It was shown in the study that delivering fluorescent nanospanlastic through the nose to the brains of rats worked. The field of fluorescent particle imaging in certain brain regions should significantly progress as a result of the findings of this study.

References

  • [1] Sun C, Lee JS, Zhang M. Magnetic nanoparticles in MR imaging and drug delivery. Adv Drug Deliv Rev. 2008;60(11):1252-1265. https://doi.org/10.1016/j.addr.2008.03.018 .
  • [2] Yu EY, Bishop M, Zheng B, Ferguson RM, Khandhar AP, Kemp SJ, Krishnan KM, Goodwill PW, Conolly SM. Magnetic particle imaging: A novel in vivo imaging platform for cancer detection. Nano Lett. 2017;17(3):1648-1654. https://doi.org/10.1021/acs.nanolett.6b04865 .
  • [3] Banks WA. From blood-brain barrier to blood-brain interface: New opportunities for CNS drug delivery. Nat Rev Drug Discov. 2016 (4):275-292. https://doi.org/10.1038/nrd.2015.21 .
  • [4] Salih OS, Al-Akkam EJ. Preparation, in-vitro, and ex-vivo evaluation of ondansetron loaded invasomes for transdermal delivery. Iraqi J Pharm Sci. 2023;32(3):71-84. https://doi.org/10.31351/vol32iss3pp71-84
  • [5] Salih O, Muhammed E. Preparation, evaluation, and histopathological studies of ondansetron-loaded invasomes transdermal gel. J Res Pharm. 2024;28(1):289-303. https://doi.org/10.29228/jrp.696 .
  • [6] Busquets MA, Espargaró A, Sabaté R, Estelrich J. Magnetic nanoparticles cross the blood-brain barrier: When physics rises to a challenge. Nanomaterials (Basel). 2015;5(4):2231-2248. https://doi.org/10.3390/nano5042231 .
  • [7] Dhuria SV, Hanson LR, Frey WH 2nd. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci. 2010;99(4):1654-1673. https://doi.org/10.1002/jps.21924 .
  • [8] Salih OS, Ghareeb MM. Formulation and in-vitro evaluation of thermosensitive ciprofloxacin HCl in-situ gel for local nasal infection. IJDDT. 2021;11(4):1295-1301. https://doi.org/10.25258/ijddt.11.4.29 .
  • [9] Lochhead JJ, Thorne RG. Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev. 2012;64(7):614-628. https://doi.org/10.1016/j.addr.2011.11.002 .
  • [10] Manar TA, Hanan KJ. Optimizing intranasal amisulpride loaded nanostructured lipid carriers: Formulation, development, and characterization parameters. Pharm Nanotechnol. 2024;(12): 1–16. https://doi.org/10.2174/0122117385301604240226111533 .
  • [11] Mistry A, Stolnik S, Illum L. Nanoparticles for direct nose-to-brain delivery of drugs. Int J Pharm. 2009 ;379(1) :146-157. https://doi.org/10.1016/j.ijpharm.2009.06.019 .
  • [12] Yang ZZ, Zhang YQ, Wang ZZ, Wu K, Lou JN, Qi XR. Enhanced brain distribution and pharmacodynamics of rivastigmine by liposomes following intranasal administration. Int J Pharm. 2013;452(1-2):344-354. https://doi.org/10.1016/j.ijpharm.2013.05.009 .
  • [13] Kanazawa T, Taki H, Tanaka K, Takashima Y, Okada H. Cell-penetrating peptide-modified block copolymer micelles promote direct brain delivery via intranasal administration. Pharm Res. 2011;28(9):2130-2139. https://doi.org/10.1007/s11095-011-0440-7 .
  • [14] Alkufi HK, Kassab HJ. Soluplus-stabilized nimodipine-entrapped spanlastic formulations prepared with edge activator (Tween20): Comparative physicochemical evaluation. Pharm Nanotechnol. 2024 Nov 4. https://doi.org/10.2174/0122117385348551241028102256
  • [15] Jaber SA, Rajab NA. Preparation and in vitro/ex vivo evaluation of nanoemulsion-based in situ gel for intranasal delivery of lasmiditan. IJPS. 2024;33(3):128-141. https://doi.org/10.31351/vol33iss3pp128-141 .
  • [16] Alkufi HK, Kassab HJ. Formulation and evaluation of sustained release sumatriptan mucoadhesive intranasal in-situ gel. Iraqi J Pharm Sci. 2019;28(2):95-104. https://doi.org/10.31351/vol28iss2pp95-104 .
  • [17] Genter MB, Newman NC, Shertzer HG, Ali SF, Bolon B. Distribution and systemic effects of intranasally administered 25 nm silver nanoparticles in adult mice. Toxicol Pathol. 2012;40(7):1004-1013. https://doi.org/10.1177/0192623312444470 .
  • [18] Alhammid SNA, Kassab HJ, Hussein LS, Haiss MA. Spanlastics nanovesicles: An emerging and innovative approach for drug delivery. Maaen J Med Sci. 2023;2(2):9. https://doi.org/10.55810/2789-9136.1027 .
  • [19] Alzalzalee RA, Kassab HJ. Effect of polymer type and concentration on preparation of cilnidipine nanoparticle (A preformulation study). Hist Med. 2023;9(1):1902–1906. https://doi.org/10.17720/2409-5834.v9.1.2023.243 .
  • [20] Salim FF, Rajab NA. Formulation and characterization of piroxicam as self-nano emulsifying drug delivery system. Iraqi J Pharm Sci. 2020;29(1):174–183. https://doi.org/10.31351/vol29iss1pp174-183 .
  • [21] Saari MM, Takagi R, Kusaka T, Ishihara Y, Tsukamoto Y, Sakai K, Kiwa T, Tsukada K. Development of integrated AC-DC magnetometer using high-Tc SQUID for magnetic properties evaluation of magnetic nanoparticles in solution. J Phys: Conf Series. 2014 :507(4): 042035. https://doi.org/10.1088/1742-6596/507/4/042035 .
  • [22] Alwan ZS, Rajab NA. Preparation and characterization of febuxostat nanosuspension as fast dissolving oral film. Al-Rafidain J Med Sci. 2024;6(2):171-177. https://doi.org/10.54133/ajms.v6i2.873 .
  • [23] Kishimoto K, Kuroda H, Tsubota M, Yamashita K, Wang J, Sakai K, Saari MM, Kiwa T. Dispersion of Fe3O4 nanoparticle beads driven by femtosecond laser pulses for quantitative magnetic immunoassay measurements. acs appl nano mater. 2022;5(11):17258-17263. https://doi.org/10.1021/acsanm.2c04399 .
  • [24] Abdulbaqi MR, Rajab NA. Preparation, characterization and ex vivo permeability study of transdermal apixaban O/W nanoemulsion based gel. Iraqi J Pharm Sci. 2020;29(2):214-222. https://doi.org/10.31351/vol29iss2pp214-222
  • [25] Alshammari MA, Khan MR, Alasmari F, Alshehri AO, Ali R, Boudjelal M, Alhosaini KA, Niazy AA, Alshammari TK. Changes in the fluorescence tracking of NaV1.6 protein expression in a BTBR T+Itpr3tf/J autistic mouse model. Neural Plast. 2019;2019:4893103. https://doi.org/10.1155/2019/4893103 .
  • [26] Chourasia MK, Kang L, Chan SY. Nanosized ethosomes bearing ketoprofen for improved transdermal delivery. Results Pharm Sci. 2011;1(1):60-67. https://doi.org/10.1016/j.rinphs.2011.10.002 .
There are 26 citations in total.

Details

Primary Language English
Subjects Pharmacology and Pharmaceutical Sciences (Other)
Journal Section Research Article
Authors

Hussein Alkufi 0000-0001-6977-6737

Hanan J. Kassab This is me 0000-0001-9590-339X

Submission Date October 26, 2024
Acceptance Date January 31, 2025
Publication Date March 15, 2026
DOI https://doi.org/10.12991/jrespharm.1909321
IZ https://izlik.org/JA79AE45SE
Published in Issue Year 2026 Volume: 30 Issue: 2

Cite

APA Alkufi, H., & J. Kassab, H. (2026). In-vivo examination of nasal-to-brain administration for delivering rhodamine B nanospanlastic for fluorescent vesicle imaging. Journal of Research in Pharmacy, 30(2), 569-575. https://doi.org/10.12991/jrespharm.1909321
AMA 1.Alkufi H, J. Kassab H. In-vivo examination of nasal-to-brain administration for delivering rhodamine B nanospanlastic for fluorescent vesicle imaging. J. Res. Pharm. 2026;30(2):569-575. doi:10.12991/jrespharm.1909321
Chicago Alkufi, Hussein, and Hanan J. Kassab. 2026. “In-Vivo Examination of Nasal-to-Brain Administration for Delivering Rhodamine B Nanospanlastic for Fluorescent Vesicle Imaging”. Journal of Research in Pharmacy 30 (2): 569-75. https://doi.org/10.12991/jrespharm.1909321.
EndNote Alkufi H, J. Kassab H (March 1, 2026) In-vivo examination of nasal-to-brain administration for delivering rhodamine B nanospanlastic for fluorescent vesicle imaging. Journal of Research in Pharmacy 30 2 569–575.
IEEE [1]H. Alkufi and H. J. Kassab, “In-vivo examination of nasal-to-brain administration for delivering rhodamine B nanospanlastic for fluorescent vesicle imaging”, J. Res. Pharm., vol. 30, no. 2, pp. 569–575, Mar. 2026, doi: 10.12991/jrespharm.1909321.
ISNAD Alkufi, Hussein - J. Kassab, Hanan. “In-Vivo Examination of Nasal-to-Brain Administration for Delivering Rhodamine B Nanospanlastic for Fluorescent Vesicle Imaging”. Journal of Research in Pharmacy 30/2 (March 1, 2026): 569-575. https://doi.org/10.12991/jrespharm.1909321.
JAMA 1.Alkufi H, J. Kassab H. In-vivo examination of nasal-to-brain administration for delivering rhodamine B nanospanlastic for fluorescent vesicle imaging. J. Res. Pharm. 2026;30:569–575.
MLA Alkufi, Hussein, and Hanan J. Kassab. “In-Vivo Examination of Nasal-to-Brain Administration for Delivering Rhodamine B Nanospanlastic for Fluorescent Vesicle Imaging”. Journal of Research in Pharmacy, vol. 30, no. 2, Mar. 2026, pp. 569-75, doi:10.12991/jrespharm.1909321.
Vancouver 1.Hussein Alkufi, Hanan J. Kassab. In-vivo examination of nasal-to-brain administration for delivering rhodamine B nanospanlastic for fluorescent vesicle imaging. J. Res. Pharm. 2026 Mar. 1;30(2):569-75. doi:10.12991/jrespharm.1909321